Regulations for Opdivo (Nivolumab) in Malignant Melanoma Treatment
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
In the field of melanoma treatment, the application of immune checkpoint inhibitors is constantly being optimized. According to the latest announcement from Ono Pharmaceutical Co., Ltd. in Japan, Opdivo (Nivolumab) has received approval in Japan for the treatment of "chemotherapy-naïve" (untreated) malignant melanoma patients. This is undoubtedly a significant milestone for many patients seeking advanced medical care in Japan.
Clinical Data: Significant Response Rates
The additional approval is primarily based on the results of two key clinical trials:
- ONE-4538-08 (Phase II Clinical Trial in Japan): Results from trials in Japanese patients showed a response rate (significant tumor shrinkage) of 29.2%.
- CA209-066 (International Clinical Trial): Overseas data further confirmed the superiority and safety of Opdivo in first-line treatment (without prior chemotherapy).
Latest Usage and Dosage Guidelines
According to the approved content, the usage of Opdivo is adjusted based on the patient's treatment history:
- First-line patients (without prior chemotherapy): The recommended dose is 3mg/kg (body weight), administered every two weeks.
- Patients with prior chemotherapy: The dose is 2mg/kg (body weight), with the option to administer every two or three weeks.
Mechanism of Immunotherapy and Economic Considerations
Opdivo works by blocking the interaction between PD-1 and PD-L1, reactivating suppressed T cells to attack cancer cells. Current clinical observations show that combining immune drugs with different mechanisms (such as Nivolumab combined with Ipilimumab) is more effective, though the corresponding side effects and financial burden also increase.
Cost Reference: In Japan, the price of Opdivo 100mg is approximately 390,000 Yen (excluding medical examination, customs, and shipping fees). Generally, four consecutive doses are required before an initial assessment of its effectiveness can be made. Due to the high cost, patients are advised to have an in-depth consultation with a professional medical team before making a decision.
Professional Support from Medical Supporter Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
#Melanoma #Opdivo #Immunotherapy #JapanMedical #OnoPharmaceutical #CancerTreatment
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.